Breast Cancer Coverage from Every Angle

Luca Gianni, MD, on Evaluating Progress With Checkpoint Inhibitors in Breast Cancer

Posted: Friday, January 17, 2020

Luca Gianni, MD, of the Fondazione Michelangelo, talks about the implications of his study on neoadjuvant atezolizumab and whether it represents the best setting for immune checkpoint inhibitors in patients with triple-negative breast cancer.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.